Welcome to LookChem.com Sign In|Join Free
  • or
1-Piperazinecarboxylic acid, 4-(cyanomethyl)-, phenylmethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

676341-78-9

Post Buying Request

676341-78-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

676341-78-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 676341-78-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,7,6,3,4 and 1 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 676341-78:
(8*6)+(7*7)+(6*6)+(5*3)+(4*4)+(3*1)+(2*7)+(1*8)=189
189 % 10 = 9
So 676341-78-9 is a valid CAS Registry Number.

676341-78-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-benzyloxycarbonyl-4-cyanomethylpiperazine

1.2 Other means of identification

Product number -
Other names 4-cyanomethyl-piperazine-1-carboxylic acid benzyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:676341-78-9 SDS

676341-78-9Relevant academic research and scientific papers

A chimeric ligand approach leading to potent antiprion active acridine derivatives: Design, synthesis, and biological investigations

Dollinger, Silke,L?ber, Stefan,Klingenstein, Ralf,Korth, Carsten,Gmeiner, Peter

, p. 6591 - 6595 (2006)

Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC50 value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 676341-78-9